Norden Gregory
SEC Form 4 insider trading activity
Norden Gregory has filed 5 SEC Form 4 filings (6 transaction rows) across 3 companies, including PRAX, RPRX, ZTS, with disclosures dating back to 2026. 5 of those filings fall inside the rolling window. Most recent filing: Jun 12, 2026.
On the most recent filing, Norden Gregory is listed as Director at Royalty Pharma plc. Inside the rolling window, Norden Gregory reported no open-market purchases and 1 open-market sale totaling $161K in RPRX.
Companies traded
Other insiders at PRAX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$161K
reported sales (SEC code S)
Companies
3
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Norden Gregory made?
Norden Gregory has filed 5 SEC Form 4 filings (6 transaction rows) across 3 companies, including PRAX, RPRX, ZTS since 2026.
Which companies does Norden Gregory trade?
Norden Gregory has filed SEC Form 4 disclosures for 3 companies, including PRAX, RPRX, ZTS.
When was Norden Gregory's most recent SEC Form 4 filing?
Norden Gregory's most recent SEC Form 4 filing on Tracefour is dated Jun 12, 2026.
What is Norden Gregory's total buy and sell value in the current window?
Inside the rolling retention window, Norden Gregory bought $0 and sold $161K based on SEC Form 4 filings.
What was Norden Gregory's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 3,045 RPRX shares on 2026-05-14, worth $161K, per SEC Form 4 filings.